Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD

Prior treatment

• Concurrent participation in a research study or a clinical trial.
• Confirmed or suspected diagnosis of pneumonitis/ILD at the time of signing ICF. This does not apply to historical pneumonitis/ILD events that have resolved prior to signing ICF.

Other

• Unable to receive SoC for the treatment and management of NSCLC including clinical or imaging assessments for up to 6 months.
• Judgment by the Investigator that the patient is unsuitable to participate in the study and/or the patient is unlikely to comply with study procedures and requirements.
• More than 2 weeks have passed from the administration of the first dose of qualifying FDA-approved treatment.

• Patient must be 18 years of age or older, at the time of signing the ICF (Informed consent).
• Have histologically or cytologically documented unresectable Stage III or Stage IV NSCLC.
• Are initiating treatment with an FDA (Food and Drug Administration)-approved immune checkpoint inhibitor (alone or in combination with other agents), antibody drug conjugate, or small molecule EGFR inhibitor.
• Minimum life expectancy of 12 weeks at the time of signing the ICF.
• Able and willing to provide written signed informed consent.
• Able and willing to use the digital health tool throughout the duration of the study.